ARMATA PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

On March 6, 2023, Armata Pharmaceuticals, Inc. (the "Company") issued a press release pertaining to topline data from a clinical trial and the dosing of the first subject in the Company's Tailwindstudy. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Form 8-K").

Furnished as Exhibit 99.2 to this Form 8-K is an updated investor presentation that the Company plans to present to certain prospective investors that the Company will also post on its website.

The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached to this Form 8-K are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

  (d) Exhibits.




     Exhibit
       No.      Description
       99.1       Press Release, dated March 6, 2023.
       99.2       Updated Investor Presentation.
       104      Cover Page Interactive Data File (embedded within Inline XBRL document).

© Edgar Online, source Glimpses